Denali Therapeutics Inc. (DNLI)

Market Cap	3.28B +18.8%
Revenue (ttm)	n/a
Net Income	-512.54M
EPS	-2.97
Shares Out	158.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,329,741
Open	21.03
Previous Close	21.61
Day's Range	20.00 - 21.53
52-Week Range	10.57 - 23.77
Beta	1.08
Analysts	Strong Buy
Price Target	29.38 (+41.93%)
Earnings Date	Feb 26, 2026

About DNLI

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzym...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 8, 2017
• Employees: 503
• Stock Exchange: NASDAQ
• Ticker Symbol: DNLI
• Website: https://www.denalitherapeutics.com

Analyst Summary

According to 10 analysts, the average rating for DNLI stock is "Strong Buy." The 12-month stock price target is $29.38, which is an increase of 41.93% from the latest price.

Price Target

$29.38

(41.93% upside)

Analyst Consensus: Strong Buy